deferoxamine has been researched along with Thrombopenia in 4 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Desferrioxamine (DFO) was administered intravenously to a 63-year-old chronic hemodialysis patient with osteomalacia believed secondary to aluminum intoxication." | 3.67 | Thrombocytopenia associated with intravenous desferrioxamine. ( Eisinger, RP; Sherman, RA; Walker, JA, 1985) |
| "Enrolled patients (9 with β-thalassemia major and 33 with β-thalassemia hemoglobin E), ranging from 3 to 18 years in age, were divided into 3 groups; group 1 ferritin ≥1,000-2,500 ng/ml (n = 10), group 2 ferritin >2,500-4,000 ng/ml (n = 23) and group 3 ferritin >4,000 ng/ml (n = 9)." | 2.80 | Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Sungkarat, W; Wongwerawattanakoon, P, 2015) |
| "Background Thrombocytopenia is common in sick neonates." | 1.46 | Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development. ( Bastian, TW; Chen, MJ; Connor, JR; Duck, KA; Georgieff, MK; Lanier, LM; Liu, ZJ; Michalopoulos, GC; Sola-Visner, MC, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Songdej, D | 1 |
| Sirachainan, N | 1 |
| Wongwerawattanakoon, P | 1 |
| Sasanakul, W | 1 |
| Kadegasem, P | 1 |
| Sungkarat, W | 1 |
| Chuansumrit, A | 1 |
| Bastian, TW | 1 |
| Duck, KA | 1 |
| Michalopoulos, GC | 1 |
| Chen, MJ | 1 |
| Liu, ZJ | 1 |
| Connor, JR | 1 |
| Lanier, LM | 1 |
| Sola-Visner, MC | 1 |
| Georgieff, MK | 1 |
| Leitch, HA | 1 |
| Vickars, LM | 1 |
| Walker, JA | 1 |
| Sherman, RA | 1 |
| Eisinger, RP | 1 |
1 review available for deferoxamine and Thrombopenia
| Article | Year |
|---|---|
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Topics: Aged; Anemia; Benzoates; Blood Component Transfusion; Chelation Therapy; Combined Modality Therapy; | 2009 |
1 trial available for deferoxamine and Thrombopenia
| Article | Year |
|---|---|
Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; beta-Thalassemia; Child; Child, Preschool; C | 2015 |
2 other studies available for deferoxamine and Thrombopenia
| Article | Year |
|---|---|
Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development.
Topics: Anemia, Iron-Deficiency; Animals; Benzoates; Biological Transport; Biomimetics; Blood-Brain Barrier; | 2017 |
Thrombocytopenia associated with intravenous desferrioxamine.
Topics: Aluminum; Deferoxamine; Humans; Hypotension; Injections, Intravenous; Kidney Failure, Chronic; Male; | 1985 |